Aprogen is a biopharmaceutical company that specializes in the development and manufacturing of innovative biotechnological products. The company focuses on several advanced technologies, including CHIMPS and SHOCAP, which are designed for the creation of bispecific antibodies. These technologies enable the targeting of multiple antigens simultaneously, enhancing therapeutic efficacy. Additionally, Aprogen employs bitargeting receptor-antibody hybrids and SDR-grafting techniques, which further optimize the specificity and functionality of their antibody-based therapies. Their recombinant protein fusion technology is also pivotal in producing complex proteins that can be used in various therapeutic applications.

In terms of product offerings, Aprogen has developed a pipeline that includes novel drugs and biosimilars, showcasing their commitment to addressing unmet medical needs. Their manufacturing capabilities are centered at the Osong Plant, which is equipped to support the production of these advanced biopharmaceuticals. The company emphasizes quality and innovation, as evidenced by their focus on hardfacing technologies and insulation certification, ensuring that their products meet rigorous industry standards. Overall, Aprogen's diverse technological portfolio positions it as a leader in the biopharmaceutical sector, dedicated to delivering high-quality therapeutic solutions.

South Korea

Biopharmaceutical company focused on developing and manufacturing biosimilar products, new protein drugs and bispecific antibodies

Cancer

Immune System Diseases

Lymphatic Diseases

Musculoskeletal Diseases

Skin Diseases

Aprogen

Autoimmune disease

GS07 (Infliximab)

Antibodies

Biologics

Breast cancer

AP06 (Trastuzumab)

Lymphoma

AP05 (Rituximab)

AP09 (Adalimumab)

Osteoarthritis

AP20

Triple-negative breast cancer

AP40

Biosimilars

Generics

Therapeutic

Aprogen

Company Details